Kedokteran & Kesehatan editorial
Open AccessOA2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma
In a multicenter phase II trial, neoadjuvant gemcitabine and split-dose cisplatin produced a 63% pathologic response rate (19% complete) in high-risk upper tract urothelial carcinoma, with 2-year progression-free and overall survival of 89% and 93%, respectively, and acceptable tolerability.
J. Coleman; W. Yip; N. Wong; D. Sjoberg; B. Bochner; G. Dalbagni; S. Donat; H. Herr; E. Cha; T. Donahue; E. Pietzak; A. Hakimi; Kwanghee Kim; H. Al-Ahmadie; H. Vargas; R. Alvim; S. Ghafoor; N. Benfante; A. Meraney; S. Shichman; J. Kamradt; S. Nair; A. Baccala; Paul Palyca; B. Lash; M. Rizvi; S. Swanson; A. Muina; A. Apolo; G. Iyer; J. Rosenberg; Min Y. Teo; D. Bajorinยท Journal of Clinical Oncologyยท 2023ยท DOI 10.1200/JCO.22.00763
The core problem
Upper tract urothelial carcinoma (UTUC) is a rare and aggressive malignancy. While neoadjuvant chemotherapy (NAC) has established survival benefits in invasive urothelial carcinoma of the bladder, its role in UTUC remains undefined. High-risk UTUC is associated with poor outcomes after surgery alone, and effective perioperative systemic therapy is urgently needed. The authors conducted a multicenter, single-arm, phase II trial to evaluate the efficacy and tolerability of NAC with gemcitabine and split-dose cisplatin (GC) before extirpative surgery in patients with high-risk UTUC. The primary objective was to determine the pathologic response rate, with secondary objectives including progression-free survival (PFS), overall survival (OS), and safety.
Innovation
Eligible patients had high-risk localized UTUC as defined by clinical criteria (e.g., high-grade histology, large tumor size, or hydronephrosis). Patients received four cycles of split-dose GC (gemcitabine plus cisplatin administered on days 1 and 8 of a 21-day cycle) followed by surgical resection and lymph node dissection. The primary endpoint was pathologic response, defined as < ypT2N0. Secondary endpoints included PFS, OS, and safety/tolerability. Pathologic response was further categorized as complete (ypT0N0) or partial. Survival analyses were performed using Kaplan-Meier methods and compared between responders and non-responders.
Introduction
Upper tract urothelial carcinoma (UTUC) is a rare and aggressive malignancy. While neoadjuvant chemotherapy (NAC) has established survival benefits in invasive urothelial carcinoma of the bladder, its role in UTUC remains undefined. High-risk UTUC is associated with poor outcomes after surgery alone, and effective perioperative systemic therapy is urgently needed. The authors conducted a multicenter, single-arm, phase II trial to evaluate the efficacy and tolerability of NAC with gemcitabine and split-dose cisplatin (GC) before extirpative surgery in patients with high-risk UTUC. The primary objective was to determine the pathologic response rate, with secondary objectives including progression-free survival (PFS), overall survival (OS), and safety.
Why it matters
The authors conclude that NAC with split-dose GC is well tolerated and effective in high-risk UTUC, yielding a high pathologic response rate that correlates with favorable survival outcomes. These survival figures compare favorably with historical series of surgery alone, supporting the use of NAC as a standard of care for high-risk UTUC. Split-dose GC is a viable option for NAC in this setting. The study is limited by its single-arm design and relatively small sample size, but the results are promising and warrant further investigation, potentially in randomized trials. The findings also highlight the importance of pathologic response as a prognostic marker in UTUC.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member contentโฆ